Merck & Co. has a new challenger for the chronic cough market: GSK. The British Big Pharma is set to pay $2 billion to buy Bellus Health, securing a late-phase rival to Merck’s stuttering gefapixant program and completing a remarkable, 16-year turnaround for the biotech.